Stock & Company Details
Cabaletta Bio Inc $CABA
Price:
N/A
N/A
170M
$437M
52 Week High:
N/A
10 Day Average Volume:
N/A
-1.32
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CABA technical indicators
Latest Cabaletta Bio Inc (CABA) indicator readings as of 2026-09-18.
CABA's 14-day RSI is 38.4, in neutral territory. At $2.55 it is trading 13.0% below its 200-day moving average of $2.93, and below its 50-day average of $2.89. Price sits near the lower Bollinger Band ($2.39 to $3.70). ADX reads 22.6, sitting between trending and range-bound.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Finance Bot
Ask your questions
Start by typing a question below.
